PharmGKB summary: Ivacaftor pathway, pharmacokinetics/pharmacodynamics

Pharmacogenetics and Genomics

Volumn 27, Issue 1, 2017, Pages 39-42

  Fohner, Alison E ^a   McDonagh, Ellen M ^c   Clancy, John P ^b   Whirl Carrillo, Michelle ^a   Altman, Russ B ^a   Klein, Teri E ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE ION; COMPLEMENTARY DNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IVACAFTOR; LUMACAFTOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ALLELE; ARTICLE; CHLORIDE TRANSPORT; CYSTIC FIBROSIS; DRUG MECHANISM; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; AGONISTS; GENETICS; PATHOLOGY;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; QUINOLONES;

EID: 84987903939     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000246     Document Type: Article

References (28)

1. Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014; 18:1-106.
2. Cant N, Pollock N, Ford RC. CFTR structure and cystic fibrosis. Int J Biochem Cell Biol 2014; 52:15-25.
3. Cystic Fibrosis Foundation. Cystic fibrosis foundation, overview; 2015. Available at: http://www.cff.org/AboutCF/. [Accessed 24 March 2016].
4. Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2103; 22:58-65.
5. Ikpa PT, Bijvelds MJ, de Jonge HR. Cystic fibrosis: toward personalized therapies. Int J Biochem Cell Biol 2014; 52:192-200.
6. Committee for Medicinal Products for Human Use. Kalydeco: assessment report. London, UK: European Medicines Agency; 2012.
7. McColley SA. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf 2016; 15:709-715.
8. Wainwright CE. Ivacaftor for patients with cystic fibrosis. Expert Rev Respir Med 2014; 8:533-538.
9. Robertson SM, Luo X, Dubey N, Li C, Chavan AB, Gilmartin GS, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 2015; 55:56-62.
10. Committee for Medicinal Products for Human Use. Kalydeco: assessment report. London, UK: European Medicines Agency; 2014.
11. Brewington JJ, McPhail GL, Clancy JP. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Expert Rev Respir Med 2016; 10:5-17.
12. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363:1991-2003.
13. Kulczycki LL, Kostuch M, Bellanti JA. A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations. Am J Med Genet A 2003; 116A:262-267.
14. Davies JC. The future of CFTR modulating therapies for cystic fibrosis. Curr Opin Pulm Med 2015; 21:579-584.
15. Jih KY, Hwang T-C. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA 2013; 110:4404-4409.
16. Kopeikin Z, Yuksek Z, Yang HY, Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros 2014; 13:508-514.
17. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237-245.
18. Davies J, Sheridan H, Bell N, Cunningham S, Davies SD, Elborn JS, et al. Assessment of clinical response to with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2013; 1:630-638.
19. Ramsey BW, Davies J, McElvaney NG, Tulis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663-1672.
20. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013; 143:14-18.
21. Barry PJ, Jones AM, Webb AK, Horsley AR. Sweat chloride is not a useful marker of clinical response to ivacaftor. Thorax 2014; 69:586-587.
22. Accurso FJ, van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 2014; 13:139-147.
23. Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106:18825-18830.
24. Gohil K. Pharmaceutical approval update. P T 2015; 40:567-568.
25. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011; 139:1480-1490.
26. Sosnay PR, Siklosi KR, van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45:1160-1167.
27. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol 2011; 117:1028-1031.
28. Ronan NJ, Fleming C, O'Callaghan G, Maher MM, Murphy DM, Plant BJ. The role of ivacaftor in severe cystic fibrosis in a patient with the R117H mutation. Chest 2015; 148:e72-e75.